De Novo device
esolution® Esophageal Retractor
S4 Medical Corp. · Esophageal Protection Device For Use In Percutaneous Cardiac Catheter Ablation Procedures, Mechanical Deviation (QXU, Class II) · First FDA decision Sep 6, 2023, newest Nov 9, 2024Atrial fibrillation
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
2
De Novo pathway
Device trials
1
Naming "esolution"
MAUDE reports
0
Brand "esolution", since 2015
PubMed studies
9
Mentioning "esolution"
AI summary across all sources
Written by Claude (Anthropic's AI) from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
FDA decisions
The newest 2 of 2 decisions filed under this name.
K243233 · Decided Nov 9, 2024 · 31 days after receipt
Device type: Esophageal Protection Device For Use In Percutaneous Cardiac Catheter Ablation Procedures, Mechanical Deviation (QXU) · Cardiology
- esolutionNew device typeDe Novo
DEN230006 · Decided Sep 6, 2023 · 225 days after receipt
Device type: Esophageal Protection Device For Use In Percutaneous Cardiac Catheter Ablation Procedures, Mechanical Deviation (QXU) · Cardiology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Cardiac Catheterization Performed In Other Than A Hospital SettingNational analysisReview closedCAG-00166NUpdated Sep 16, 2026
- Cardiac Catheterization Performed in Other than a Hospital Setting - RETIREDNational determinationOn the books20.25Updated Dec 3, 2024
- Cardiac Catheterization and Coronary AngiographyLocal determinationIn effectL33959CGS Administrators, LLCUpdated Oct 30, 2026
- Cardiac Catheterization and Coronary AngiographyLocal determinationIn effectL33557Wellpoint FederalUpdated Jul 14, 2026
Clinical trials
Device studies on ClinicalTrials.gov that name "esolution", any status and sponsor, newest update first.
- Esophagus Deviation During Radiofrequency Ablation of Atrial Fibrillation - EASY AF STUDYPivotal-lookingCompleted
S4 MedicalNot on our public-company list
NCT04659213 · 129 participants · Start Sep 1, 2021 · Primary completion Jun 30, 2022
Device: esolution catheter · For: Atrial Fibrillation
Sites: Columbus, Ohio
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "esolution", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code QXU
0 reports: 0 malfunction, 0 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "esolution"[tiab]. The summary above synthesizes these.
- Hydrogel In-Tape Electronic Tongue.
Brito-Pereira R, Policia R, Ribeiro C, et al. · ACS Appl Electron Mater · 2025
- Accuracy of Cone-beam Computed Tomography and Extraoral Bitewings Compared to Intraoral Bitewings in Detection of Interproximal Caries.
Felemban OM, Loo CY, Ramesh A · J Contemp Dent Pract · 2020
- Sulfur-containing nucleoside from yeast transfer ribonucleic acid: 2-thio-5(or 6)-uridine acetic acid methyl ester.
Baczynskyj L, Biemann K, Hall RH · Science · 1968
- ORMAN: optimal resolution of ambiguous RNA-Seq multimappings in the presence of novel isoforms.
Dao P, Numanagik I, Lin YY, et al. · Bioinformatics · 2014Research Support, Non-U.S. Gov't
- Single-molecule nanopore-tweezers analysis of transcription elongation by intact and "stalk-less" yeast RNA polymerase II.
Yang S, Chen M, Laszlo AH, et al. · bioRxiv · 2026Preprint
- Adherence of the #Here4U App - Military Version to Criteria for the Development of Rigorous Mental Health Apps.
Linden B, Tam-Seto L, Stuart H · JMIR Form Res · 2020
- Development of a sampling method for carbonyl compounds released due to the use of electronic cigarettes and quantitation of their conversion from liquid to aerosol.
Jo SH, Kim KH · J Chromatogr A · 2016Research Support, Non-U.S. Gov't, Validation Study
- Pulse radiolysis of nucleic acid constituents and related compounds. II. esolution of a rapidly decaying transient absorption in cytosine solutions.
Myers LS, Warnick A, Hollis ML, et al. · J Am Chem Soc · 1970
- Beyond connectivity: what the success of one health plan's e-solution means for the future of the healthcare industry.
Riley T, Korpman RA · J Healthc Inf Manag · 2001
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.